| P50 | author | James Januzzi | Q63144011 |
| P2093 | author name string | Robert E Gerszten | |
| | Marielle Scherrer-Crosbie | |
| | Bonnie Ky | |
| | Michael H Picard | |
| | Benjamin French | |
| | Elkan F Halpern | |
| | Susan E Wiegers | |
| | Heloisa Sawaya | |
| | Igal A Sebag | |
| | Irene Kuter | |
| | Jonathan Passeri | |
| | Jose Banchs | |
| | Joseph R Carver | |
| | Juan Carlos Plana | |
| | Mary Putt | |
| | Randolph P Martin | |
| | Victor Cohen | |
| P2860 | cites work | Cardiac dysfunction in the trastuzumab clinical trials experience | Q28204298 |
| | Use of multiple biomarkers to improve the prediction of death from cardiovascular causes | Q28280099 |
| | Biomarkers in heart failure | Q28280109 |
| | Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy | Q33202989 |
| | Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation | Q33647686 |
| | Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure | Q34032111 |
| | Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials | Q34199968 |
| | Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 |
| | Multiple biomarkers for risk prediction in chronic heart failure. | Q36070049 |
| | Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study | Q36207305 |
| | The relevance of information generated by in vitro experimental models to clinical doxorubicin cardiotoxicity | Q36590959 |
| | Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab | Q36988278 |
| | Early detection and prediction of cardiotoxicity in chemotherapy-treated patients | Q36988282 |
| | Cardiovascular toxicity caused by cancer treatment: strategies for early detection | Q37430831 |
| | Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure | Q40203262 |
| | Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. | Q42626922 |
| | Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients | Q44035774 |
| | Use of myeloperoxidase for risk stratification in acute heart failure. | Q54261762 |
| | Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non ST-Elevation Acute Coronary Syndrome | Q56593478 |
| | Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio | Q57217547 |
| | Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib | Q57578352 |
| | Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice | Q71119918 |
| | Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes | Q73894487 |
| | Biologic variation of a novel cardiac troponin I assay | Q83964021 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| | patient | Q181600 |
| | trastuzumab | Q412616 |
| | biomarker | Q864574 |
| | breast cancer | Q128581 |
| P304 | page(s) | 809-816 | |
| P577 | publication date | 2013-11-27 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab | |
| P478 | volume | 63 | |